Compare Corning Incorporated (GLW) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs GSK plc — how do they compare? Corning Incorporated trades at $156.45 (market cap $131.65B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: Corning Incorporated is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and GSK plc for 93 Days on average.
| GLW | GSK | |
|---|---|---|
Market Cap | $131.65B | $91.88B |
Volume | 8,992,522 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $255.79 | $61.18 |
52-Week Low | $78.03 | $43.24 |
Typical Hold Time | 36 Days | 93 Days |
Enterprise Value | $138.52B | $111.88B |
Dividend Yield | 0.73% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $156.69, down 3.99% amid a bearish technical signal, though fundamentals show strong recovery with 2025 revenue reaching $15.63B and net income surging to $1.60B. The company recently secured a multi-year $3B fiber supply deal with AT&T, boosting its optical communications segment. Analyst consensus remains positive with a $171.25 price target and 57% buy ratings, but technical indicators show selling pressure with support at $149.
GLW presents a mixed outlook: the AT&T deal and earnings beat streak support growth, but high valuation ratios (P/E 70.43) and bearish technicals pose near-term risks. Investors should weigh strong cash flow projections ($1.0B net CF in 2026) against patent litigation concerns and elevated debt levels. The stock offers upside to analyst targets if execution continues.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
